Spark Therapeutics Inc (NASDAQ:ONCE) Given Average Rating of “Hold” by Brokerages

Share on StockTwits

Shares of Spark Therapeutics Inc (NASDAQ:ONCE) have earned an average recommendation of “Hold” from the thirteen research firms that are covering the firm, Marketbeat.com reports. Thirteen investment analysts have rated the stock with a hold recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $106.00.

A number of analysts recently issued reports on ONCE shares. Zacks Investment Research upgraded Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, December 3rd. ValuEngine downgraded Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd.

ONCE traded down $0.99 during trading on Friday, reaching $110.91. The company had a trading volume of 29,833 shares, compared to its average volume of 891,690. The stock has a market cap of $4.29 billion, a P/E ratio of -52.68 and a beta of 2.05. The business has a 50 day simple moving average of $109.91 and a 200-day simple moving average of $103.36. Spark Therapeutics has a 52 week low of $34.53 and a 52 week high of $114.20. The company has a quick ratio of 4.35, a current ratio of 4.67 and a debt-to-equity ratio of 0.35.

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in shares of Spark Therapeutics by 4,568.4% during the third quarter. Tower Research Capital LLC TRC now owns 887 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 868 shares during the last quarter. CSat Investment Advisory L.P. bought a new stake in shares of Spark Therapeutics during the second quarter worth $113,000. Nisa Investment Advisors LLC lifted its position in shares of Spark Therapeutics by 651.6% during the third quarter. Nisa Investment Advisors LLC now owns 1,165 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,010 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Spark Therapeutics during the second quarter valued at $202,000. Finally, Ancora Advisors LLC purchased a new position in shares of Spark Therapeutics during the second quarter valued at $205,000. Institutional investors and hedge funds own 88.37% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Featured Article: What Does a Sell-Side Analyst Rating Mean?

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bank of Cyprus  Reaches New 12-Month Low at $1.32
Bank of Cyprus Reaches New 12-Month Low at $1.32
Vanguard Large-Cap ETF  Reaches New 1-Year High at $152.72
Vanguard Large-Cap ETF Reaches New 1-Year High at $152.72
Medical Properties Trust, Inc.  Shares Sold by Convergence Investment Partners LLC
Medical Properties Trust, Inc. Shares Sold by Convergence Investment Partners LLC
Outfront Media  Reaches New 52-Week High at $29.00
Outfront Media Reaches New 52-Week High at $29.00
iShares S&P 100 ETF  Hits New 12-Month High at $149.03
iShares S&P 100 ETF Hits New 12-Month High at $149.03
Frequency Therapeutics  Reaches New 1-Year High at $27.57
Frequency Therapeutics Reaches New 1-Year High at $27.57


© 2006-2020 Ticker Report